This study uncovers how HDAC11 activation promotes pro-inflammatory cytokine production in diabetes, suggesting potential therapeutic targets for vascular health.
Abstract Diabetes mellitus is marked by chronic low-grade inflammation, increasing the risk of infections and vascular complications. In this study, we uncover a novel link between bacterial infection and epigenetic regulation in diabetes. We found that infection with Escherichia coli strongly induces the expression of histone deacetylase 11 (HDAC11) in endothelial cell-derived induced pluripotent stem cells (iPS-ECs) from diabetic donors. This upregulation of HDAC11 correlated with a surge in pro-inflammatory cytokine production and marked endothelial dysfunction. Strikingly, treatment with an HDAC11-specific inhibitor significantly dampened inflammatory signaling and restored endothelial function, pointing to a potential therapeutic strategy. Further mechanistic insights revealed a direct interaction between HDAC11 and STAT3, a key regulator of inflammatory gene expression. These findings position HDAC11 as a critical mediator of infection-induced vascular inflammation in diabetes and highlight it as a promising epigenetic target to combat endothelial damage and improve vascular health in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Margariti et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: